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ABSTRACT Kaposi’ssarcoma(KS)iscausedbyKaposi’ssarcoma-associatedherpesvirus(KSHV;humanherpesvirus8).KSisan
AIDS-deﬁningcancer,anditischanginginthepost-antiretroviraltherapy(post-ART)era.Incountrieswithreadyaccessto
ART,approximatelyone-thirdofKScasespresentinpatientswithundetectableHIVloadsandCD4countsof >200cells/l.
Thisisincontrasttopre-ARTeraKS,whichwasassociatedwithsystemicHIVreplicationandCD4countsof <200cells/l.Us-
ingprimarypatientbiopsyspecimens,weidentiﬁedanovelmolecularsignaturethatcharacterizesAIDSKSlesionsthatdevelop
inHIV-suppressedpatientsonART:KSHVtranscriptionislimitedinHIV-suppressedpatients.Withoneexception,onlythe
canonicalvirallatencymRNAsweredetectable.Incontrast,earlyAIDSKSlesionsexpressedmanymoreviralmRNAs,including,
forinstance,theviralGprotein-coupledreceptor(vGPCR).
IMPORTANCE ThisistheﬁrstgenomewidestudyofKaposi’ssarcoma-associatedherpesvirus(KSHV)transcriptioninKSlesions
inthepost-antiretroviral(post-ART)era.ItshowsthatthegeneexpressionofKSHVisalteredinpatientsonART,anditpro-
videsclinicalevidenceforactiveAIDS(ascharacterizedbyhighHIVloadandlowCD4counts)beingapotentialmodulatorof
KSHVtranscription.Thisimpliesanovelmodeofpathogenesis(tightlylatentKS),whichmayinformKScancertreatmentop-
tionsinthepost-ARTera.
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K
aposi’s sarcoma (KS) is an acquired immune deﬁciency syn-
drome (AIDS)-deﬁning condition. Even after the introduc-
tion of antiretroviral therapy (ART), KS has continued to cause
morbidity and mortality in human immunodeﬁciency virus
(HIV)-infectedindividuals(1).KSrequiresinfectionwiththeKa-
posi’s sarcoma-associated herpesvirus (KSHV) (2, 3). The risk of
KS among individuals infected with KSHV is increased by poorly
controlledHIVinfectionorimmunesuppression,asmeasuredby
low CD4 T-lymphocyte counts (4, 5).
However, we and others have observed that KS can persist or
develop de novo in patients on long-term ART, despite high CD4
counts and despite undetectable HIV in plasma (6, 7). This is not
entirelyunexpectedsincetheclassic(HIV-negative)formofKSis
notassociatedwithsigniﬁcantimmunosuppression(8).Histolog-
ically, KS lesions can be classiﬁed into patch, plaque, and nodal
stages, but molecular markers of KS subclasses are missing. We
observedpreviouslythatAIDSKSlesionsvariedintheirpatternof
KSHV mRNA levels. Some exhibited high-level KSHV lytic gene
transcription, whereas others expressed only the limited set of
viral latent genes (9, 10). Here, we set out to molecularly classify
AIDSKSthatdevelopedinthepresenceofsuccessfulART(i.e.,in
the absence of ongoing HIV replication).
Deidentiﬁed skin KS biopsy specimens were collected from
maleindividualsonhighlyactiveART(HAART)after2004witha
mean age of 40 years, undetectable HIV viral load (limit of detec-
tion,50copies/ml),andCD4countsof200cells/l.ThemRNA
was isolated, and KSHV gene expression was determined by real-
time quantitative PCR (qPCR) as described previously (10).
Evidence of KSHV lytic mRNAs was found in only 1 out of 8
(13%) KS biopsy specimens from HIV-suppressed patients col-
lected after 2004 (Fig. 1). In comparison, 7 out of 11 (63%) KS
biopsy specimens from patients with fulminant AIDS and CD4
counts below 200 cells/l (median CD4 count, 33 cells/l, with
standard error of the mean [SEM] of 23 cells), which were col-
lectedbetween1996and1998,showedevidenceoflyticmRNAs(P
 0.005 by Fisher’s exact test). Biopsy specimens with a “lytic”
KSHV proﬁle had (i) many more detectable lytic mRNA tran-
scripts,aswellas(ii)higherlevelsoflyticmRNAsonanindividual
gene basis. KSHV latency-associated nuclear antigen (LANA)
mRNA is not depicted in Fig. 1, since it was used for normaliza-
tion. Note that the primer 73 5= untranscribed region (5=UTR)
(noted by * in Fig. 1), which measures the spliced form of the
5=UTR of the major KSHV latency transcript, was present in all
samples.
Two types of normalization were possible in order to compare
mRNA levels across multiple samples. Either all mRNA levels in a
sample could be normalized to a cellular standard, one (or more
[11]) so-called “housekeeping gene,” or all mRNAs could be nor-
malized to a viral standard mRNA.
The -actin mRNA level for HIV-suppressed patients had a
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val (CI) of 24.69 to 28.68. The -actin mRNA level for a group of
AIDS KS samples had a mean CT of 29.31 with a 95% CI of 26.52
to 32.10. There was no statistical difference in the -actin levels
based on the Welch two-sample t test. If anything, we had slightly
moremRNAfromthepost-HAARTbiopsyspecimens,andthusa
higher sensitivity of detecting lytic KSHV mRNAs if there were
any. This suggests that the lack of lytic mRNA detection in the
HIV-suppressed KS lesions was not due to lesser sensitivity or
systematic technical differences among both groups, but reﬂects
the biology of the virus.
BasedonourrecentexperienceinanalyzingKSmRNAlevelsin
clinicaltrials(12,13),wechoosetonormalizetoacommonstable
mRNA that encodes latency-associated nuclear antigen (LANA),
vCycl, and vFLIP (9). This mRNA as well as the LANA protein is
expressed in every KSHV-infected KS tumor cell, latent and lytic,
based on in situ studies (9, 14). The level of this “tricistronic”
mRNA does not change dramatically upon reactivation in pri-
mary effusion lymphoma (PEL) (15, 16) and is also present upon
replication in endothelial cells (17). We therefore normalized all
mRNA signals to LANA gene expression. Normalizing to LANA
mRNA thus normalized to the number of KS tumor cells within a
biopsy specimen rather than nonneoplastic tumor inﬁltrating
and/orstromalcells.Figure2Cdemonstratestheheterogeneityof
KSlesionswithregardtoLANA-expressingcells.Thisusesalarger
data set of KS lesions in HIV-suppressed patients than that in
reference 13. The mRNA levels of two different so-called house-
keeping genes, coding for actin and hypoxanthine phosphoribo-
syltransferase (HPRT), correlated well (Pearson correlation, r 
0.85) (Fig. 2C). The mRNA levels of two different latent genes,
codingforvCycandLANA,correlatedwell(Pearsoncorrelation,r
0.96).However,thecorrelationbetweeneitherviralmRNAand
either host mRNA was substantially lower, with a mean of 0.54
andarangeof0.45to0.64.ThisatteststothefactthatdifferentKS
lesions contain different numbers of KSHV-infected cells. The
possibilitytothusfactoroutnon-tumorcellsrepresentsoneofthe
major advantage of using viral mRNA levels as biomarkers as op-
posed to cellular mRNAs, for which it is often not possible to
discern between tumor cell inherent changes and changes due to
differences in tumor content within a biopsy specimen.
Median mRNA levels for each gene were computed (Fig. 2B).
EveryKSHVlyticmRNAwaspresentathigherlevelsinKSbiopsy
specimensfromtheearlyART,high-HIV,low-CD4patientscom-
pared to post-ART KS samples from patients with undetectable
HIV loads. The average difference was 3.77-fold with 95% CI of
2.97- to 4.56-fold and P  0.005 by paired Wilcoxon’s rank sum
testofmediansforeachmRNA.Thetwoexceptions(indicatedby
* in Fig. 2A) were orf26 and orf61.
Within-group variation in mRNA levels was higher for KS bi-
opsyspecimensfrompatientsinthepre-HAARTeracomparedto
biopsy specimens from HIV-suppressed KS patients, with a mean
difference of standard deviations (SDs) between groups of a 2.32
CT (95% CI, 1.95 to 2.68; P  0.005 by paired Wilcoxon’s rank
sum test). As expected, latent viral mRNAs were most abundant
and varied the least. Analysis of residuals identiﬁed the following
genes that did not differ between groups: the KSHV latent genes
coding for vCYC and LANA, but also orf10, orf17, orf44, orf46,
and orf75 and the K7 and kBZIP genes.
Representative examples of individual mRNAs are shown in
Fig. 2B. As expected, the levels of a latent mRNA, vCYC, did not
FIG 1 Unsupervised cluster analysis of KSHV transcription in KS (heat map
representation).ShownarerelativelevelsofKSHVmRNAsinKSbiopsyspec-
imens obtained from patients with low CD4 counts and detectable HIV viral
loads (pre) or with CD4 200 and no detectable HIV (post). Red indicates
maximal, yellow intermediate, and white low levels of individual mRNAs.
With the exception of a single case (arrow at bottom), none of the post-
HAART KS biopsy specimens show evidence of KSHV lytic mRNAs. In con-
trast, in 50% of lesions from pre-HAART KS, the full complement of lytic
mRNAs was detectable.
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GPCRhomolog(anearlylyticmRNA)werelowerinlesionsfrom
HIV-suppressed patients.
Next, we compared the pattern of lytic mRNA levels in KS
biopsyspecimenstothepatternoflyticmRNAsinPEL.Wesawno
signiﬁcant correlation between lytic mRNAs in KS and those in
PEL after viral reactivation (data not shown): i.e., those that are
part of the canonical cascade of gene expression leading to suc-
cessful viral replication, viral egress, and consequent host cell
death(18).ThissuggeststhatwithinaKSlesion,KSHVexpression
is dysregulated. It does not seem to follow the highly ordered
cascade of gene expression needed for viral replication, and many
KSHV proteins that were classiﬁed as lytic, based on early studies
in PEL, seem to serve a function in tumorigenesis as well as for
virus production. The precedent here is the K1 protein, which we
found in a subset of KS lesions (19), even though the gene coding
forithadbeenclassiﬁedasa“lytic”gene.AnotheroneisK2/vIL6,
which responds directly to interferon
(IFN) signaling in the absence of produc-
tive replication and to the viral transacti-
vator RTA (replication and transcription
activator) in the context of viral reactiva-
tion and replication (20). Culture-based
studies also lend credence to the involve-
ment of many more than the canonical
latent genes in KS pathogenesis. Grund-
hoff and Ganem postulated a role for in-
termittent lytic reactivation for KSHV
persistence (21), and Chandriani and
Ganem recently found evidence for vari-
able, but signiﬁcant expression of vIL6
and K1 in PEL cell lines (22). This is the
ﬁrstreportofthisphenomenoninclinical
KS biopsy specimens.
Implications for clinical studies.
AIDS KS takes a more aggressive clinical
coursethantransplant-associatedorclas-
sic KS (reviewed in reference 23). Classic
KS in particular is associated with minus-
cule amounts of systemically circulating
virus (24). Our study provides new evi-
dence for a postulated role of HIV in
AIDS KS, perhaps through HIV-tat (25)
orperhapsthroughcellularcytokinesthat
reactivateKSHVinthesettingoflowCD4
T cells. There exists another explanation
with potentially great clinical relevance.
Particular drugs within the ART regimen
could stymie KSHV reactivation and rep-
lication. One such candidate drug, nelﬁ-
navir, has recently emerged (26). Finally,
to borrow from detailed insights into
HSV-1reactivation(27),itmaybethatin
patients with high CD4 counts there ex-
ists a sufﬁcient number of KSHV cognate
CD8cells,whicheventhoughtheycannot
prevent lesion occurrence per se, may
limit viral reactivation and rapidly elimi-
nate cells that express lytic KSHV pro-
teins. There are limitations to this inter-
pretation, which need further studies. We could not separate the
effect of HIV levels from CD4 depletion, as these were coupled
AIDS KS. We also cannot discern the impact of different ART
regimens with regard to KSHV transcription. It is quite possible
that particular drug regimens inﬂuence KS and KSHV differen-
tially (28).
By proﬁling KSHV mRNAs genomewide, we ﬁnd evidence for
two molecular classes of KS: those with a “lytic” viral mRNA pro-
ﬁle,asdeﬁnedbydetectablemRNAlevelsfor50%ofviralgenes,
andthosewithtightlylatentKSHV.Thiswasnotaconsequenceof
copy number or fraction of infected cells, as in our comparisons,
the signals were normalized to the constitutive viral LANA
mRNA. This is the ﬁrst study of KS lesions from HIV-suppressed
KS patients in the post-HAART era. It establishes a novel bio-
marker for the stratiﬁcation of KS.
We speculate that KS lesions that express viral lytic proteins,
suchastheviralthymidinekinaseortheviralphosphorylase,may
FIG2 (A)Three-pointmovingaveragesofmeanKSHVmRNAlevelsinKSbiopsyspecimensfromthe
patients with low CD4 counts (solid line) and patients with undetectable HIV load and CD4 counts of
200 (open circles). Since real-time qPCR is quantitative within an extended linear range, we calcu-
lated the relative abundance of each viral mRNA compared to LANA mRNA as 1.8CT(LANA) and
expressed it as percentage of LANA mRNA on a logarithmic scale (vertical axis). (B) Pairwise compar-
isons of individual KSHV mRNAs. Shown are box plots for the levels of two KSHV lytic mRNAs
(v-cyclin [cyc], vGPCR) relative to a KSHV latent mRNA (LANA). The vertical axis is on a log10 scale.
The horizontal labels signify patients with AIDS or nondetectable HIV KS. The bold horizontal line
indicates the median, box ends the lower and upper quartiles, and dotted lines the range of the data.
Outliers are indicated by dots. (C) Pairwise correlations of log2 mRNA levels (CT) for the two cellular
genes coding for actin (hu. actin) and hypoxanthine-guanine phosphoribosyltransferase (HPRT) and
twolatentviralgenescodingfortheviralcyclin(orf72f1)andLANA(lat273F),whichoriginatefromthe
same constitutive promoter. Note that higher mRNA levels correspond to lower CT numbers. Shown
arescatterplotsandalinearregressionﬁtlinebelowthediagonal,distributionofCTsfortheindividual
genes across all samples on the diagonal, and pairwise Pearson correlation coefﬁcients above the diag-
onal of this panel matrix.
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jority of lesions in HIV-suppressed individuals are not.
Viral RNA proﬁling. RNA was isolated and analyzed by real-
time qPCR for all KSHV mRNAs as previously described (18). All
primers have a predicted melting temperature (Tm)o f6 0 1°C.
Real-time qPCR was conducted under universal cycling condi-
tions (40 cycles) with SYBR green dye as the method of detection.
The ﬁnal primer concentration was 250 nM in a total 20.0-l
reaction. Total RNA was isolated using triazole (Sigma, Inc.) and
subjected to DNase I treatment (Zymed, Inc.). RNA was reverse
transcribed using a cDNA archive kit (Applied Biosystems, Inc.).
RNA integrity was evaluated using an Agilent 2100 bioanalyzer
series C and software (Agilent, Inc.) and qPCR conducted on an
Opticon-2 MJR instrument (Bio-Rad Inc.). The instrument error
was6%.Controlreactions(reversetranscriptase[RT]negative)
were uniformly negative. All measurements were conducted in
triplicate.
The mean cycle threshold (CT) values, representing relative
mRNA abundance on a log2 scale, were ﬁrst normalized to KSHV
latency-associatednuclearantigen(LANA)mRNAandthenstan-
dardized (Z-transformation [29]) to the median of each biopsy
specimen. We did not ﬁnd a correlation between variability of
gene expression as measured by SD and overall expression levels
(data not shown). This demonstrates that the data were not bi-
ased.
Unsupervised clustering was conducted using Arrayminer
(Optimaldesign, Inc.). Additional calculations were performed in
R, version 2.5.0. The linear trend was computed using robust re-
gression (30).
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